SI3518933T1 - Metode zdravljenja materničnih miom in endometrioze - Google Patents

Metode zdravljenja materničnih miom in endometrioze

Info

Publication number
SI3518933T1
SI3518933T1 SI201731123T SI201731123T SI3518933T1 SI 3518933 T1 SI3518933 T1 SI 3518933T1 SI 201731123 T SI201731123 T SI 201731123T SI 201731123 T SI201731123 T SI 201731123T SI 3518933 T1 SI3518933 T1 SI 3518933T1
Authority
SI
Slovenia
Prior art keywords
endometriosis
methods
uterine fibroids
treating uterine
treating
Prior art date
Application number
SI201731123T
Other languages
English (en)
Inventor
Brendan Mark Johnson
Lynn Seely
JR. Paul N. MUDD
Susan Wollowitz
Mark Hibberd
Masataka Tanimoto
Vijaykumar Reddy Rajasekhar
Mayukh Vasant Sukhatme
Original Assignee
Myovant Sciences Gmbh
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60915460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3518933(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Myovant Sciences Gmbh, Takeda Pharmaceutical Company Limited filed Critical Myovant Sciences Gmbh
Publication of SI3518933T1 publication Critical patent/SI3518933T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Surgical Instruments (AREA)
SI201731123T 2016-09-30 2017-09-29 Metode zdravljenja materničnih miom in endometrioze SI3518933T1 (sl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662402055P 2016-09-30 2016-09-30
US201662402034P 2016-09-30 2016-09-30
US201662402150P 2016-09-30 2016-09-30
US201762492839P 2017-05-01 2017-05-01
US201762528409P 2017-07-03 2017-07-03
PCT/EP2017/074907 WO2018060501A2 (en) 2016-09-30 2017-09-29 Methods of treating uterine fibroids and endometriosis
EP17823018.1A EP3518933B1 (en) 2016-09-30 2017-09-29 Methods of treating uterine fibroids and endometriosis

Publications (1)

Publication Number Publication Date
SI3518933T1 true SI3518933T1 (sl) 2022-06-30

Family

ID=60915460

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201731123T SI3518933T1 (sl) 2016-09-30 2017-09-29 Metode zdravljenja materničnih miom in endometrioze

Country Status (22)

Country Link
US (4) US11033551B2 (sl)
EP (2) EP4094766A1 (sl)
JP (1) JP7043503B2 (sl)
CN (1) CN110312512B (sl)
AU (1) AU2017336363B2 (sl)
BR (1) BR112019006227A2 (sl)
CA (1) CA3038879A1 (sl)
CY (1) CY1125254T1 (sl)
DK (1) DK3518933T3 (sl)
ES (1) ES2912929T3 (sl)
HR (1) HRP20220708T1 (sl)
HU (1) HUE059101T2 (sl)
IL (2) IL300580A (sl)
LT (1) LT3518933T (sl)
MD (1) MD3518933T2 (sl)
MX (1) MX2019003726A (sl)
NZ (1) NZ752916A (sl)
PL (1) PL3518933T3 (sl)
PT (1) PT3518933T (sl)
RS (1) RS63300B1 (sl)
SI (1) SI3518933T1 (sl)
WO (1) WO2018060501A2 (sl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA46361A (fr) 2016-09-30 2021-03-31 Myovant Sciences Gmbh Traitement du cancer de la prostate
JP7043503B2 (ja) 2016-09-30 2022-03-29 ミオバント サイエンシズ ゲーエムベーハー 子宮筋腫及び子宮内膜症を治療する方法
AU2018280741B2 (en) 2017-06-05 2023-12-21 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
CN110996956A (zh) 2017-06-05 2020-04-10 奥布赛瓦股份公司 用于治疗子宫内膜异位症的促性腺激素释放激素拮抗剂给药方案
WO2019203870A1 (en) 2018-04-19 2019-10-24 Abbvie Inc. Methods of treating heavy menstrual bleeding
CA3117092A1 (en) * 2018-10-29 2020-05-07 ObsEva S.A. Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
RU2711658C1 (ru) * 2019-04-16 2020-01-20 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" Способ лечения наружного генитального эндометриоза
CN110194776B (zh) * 2019-06-27 2021-05-28 四川伊诺达博医药科技有限公司 一种瑞卢戈利的合成方法
CN114466665A (zh) * 2019-08-08 2022-05-10 奥布赛瓦股份公司 用于治疗雌激素依赖性病症的组合物和方法
CN115175912A (zh) * 2019-10-10 2022-10-11 梦欧文科学有限责任公司 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n′-甲氧基脲的结晶溶剂化形式
JP2022551316A (ja) * 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
CN113384581B (zh) * 2020-03-12 2023-11-14 成都倍特药业股份有限公司 一种包含促性腺激素释放激素拮抗剂的药物组合物
MX2022015003A (es) 2020-05-29 2023-03-03 Myovant Sciences Gmbh Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina.
EP4243829A1 (en) 2020-11-11 2023-09-20 Myovant Sciences GmbH Methods of administering relugolix
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
WO2024015934A2 (en) * 2022-07-13 2024-01-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of diagnostic screening and early detection of adenomyosis

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US402150A (en) 1889-04-30 Broadcast seed-sower
US528409A (en) 1894-10-30 Denis ahern
US402034A (en) 1889-04-23 Dumping-wagon
US492839A (en) 1893-03-07 Key for brake-shoes
US402055A (en) 1889-04-23 Water-motor
FR2512732A1 (fr) 1981-09-14 1983-03-18 Raffinage Cie Francaise Procede de fabrication d'objets composes d'un materiau rigide expanse a base de polychlorure de vinyle, objets obtenus par ce procede et leurs applications
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
ECSP961635A (es) 1996-01-11 1997-06-27 Desprendimiento controlado de esteroides del recubrimiento de azucar
ECSP971998A (es) 1997-01-15 1998-04-07 Desprendimiento controlado de esteroides del recubrimiento de azucar
DE19815060A1 (de) 1998-04-03 1999-10-14 Jenapharm Gmbh Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie
US6265393B1 (en) * 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
RU2233284C2 (ru) 1999-03-24 2004-07-27 Такеда Кемикал Индастриз, Лтд. Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона
AU2001234188A1 (en) 2000-02-29 2001-09-12 Takeda Chemical Industries Ltd. Processes for the production of thienopyrimidine derivatives
WO2003064429A1 (fr) 2002-01-30 2003-08-07 Takeda Chemical Industries, Ltd. Thienopyrimidines, procedes de fabrication et d'utilisation correspondants
KR101074462B1 (ko) 2003-01-29 2011-10-18 다케다 야쿠힌 고교 가부시키가이샤 티에노피리미딘 화합물 및 그 용도
ES2314448T3 (es) 2003-07-07 2009-03-16 Neurocrine Biosciences, Inc. Derivados de pirimidina-2,4-diona como antagonistas del receptor de la hormona de liberacion de la gonadotropina.
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
MX2008000820A (es) 2005-07-22 2008-03-18 Takeda Pharmaceutical Agente preventivo de ovulacion prematura.
AR058584A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
PA8775801A1 (es) 2007-04-06 2009-05-15 Neurocrine Biosciences Inc Antagonista del receptor de la hormona liberadora de gonadotropina y procedimientos relacionados con los mismos
US8765948B2 (en) 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
EP2329823A4 (en) 2008-09-03 2013-04-03 Takeda Pharmaceutical METHOD FOR IMPROVING CAPACITY OF PREPARATION TO BE ABSORBED AND PREPARATION WHICH CAPACITY TO BE ABSORBED IS IMPROVED
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
KR20150039882A (ko) 2010-06-16 2015-04-13 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
JP2012077020A (ja) 2010-09-30 2012-04-19 Mochida Pharmaceut Co Ltd ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬
SI2900675T1 (sl) 2012-09-28 2019-06-28 Takeda Pharmaceutical Company Limited Postopek za pridobivanje tienopirimidin derivata
EP2968566A1 (en) * 2013-03-15 2016-01-20 AbbVie Inc. Compositions for use in treating heavy menstrual bleeding and uterine fibroids
WO2016136849A1 (ja) 2015-02-26 2016-09-01 武田薬品工業株式会社 固形製剤
US9949974B2 (en) 2015-09-01 2018-04-24 Abbvie Inc. Methods of adminstering elagolix
JP7043503B2 (ja) 2016-09-30 2022-03-29 ミオバント サイエンシズ ゲーエムベーハー 子宮筋腫及び子宮内膜症を治療する方法
MA46361A (fr) 2016-09-30 2021-03-31 Myovant Sciences Gmbh Traitement du cancer de la prostate
CN110996956A (zh) 2017-06-05 2020-04-10 奥布赛瓦股份公司 用于治疗子宫内膜异位症的促性腺激素释放激素拮抗剂给药方案
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
CN115175912A (zh) 2019-10-10 2022-10-11 梦欧文科学有限责任公司 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n′-甲氧基脲的结晶溶剂化形式
MX2022015003A (es) 2020-05-29 2023-03-03 Myovant Sciences Gmbh Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina.
EP4243829A1 (en) 2020-11-11 2023-09-20 Myovant Sciences GmbH Methods of administering relugolix
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea

Also Published As

Publication number Publication date
AU2017336363A1 (en) 2019-05-16
MX2019003726A (es) 2019-09-26
US11957684B2 (en) 2024-04-16
PT3518933T (pt) 2022-05-10
CA3038879A1 (en) 2018-04-05
CN110312512A (zh) 2019-10-08
JP2019529575A (ja) 2019-10-17
PL3518933T3 (pl) 2022-06-20
BR112019006227A2 (pt) 2019-06-18
LT3518933T (lt) 2022-06-10
CY1125254T1 (el) 2024-02-16
DK3518933T3 (da) 2022-05-30
US11793812B2 (en) 2023-10-24
US20190262346A1 (en) 2019-08-29
MD3518933T2 (ro) 2022-07-31
WO2018060501A2 (en) 2018-04-05
IL265700A (en) 2019-05-30
IL265700B2 (en) 2023-07-01
JP7043503B2 (ja) 2022-03-29
US20240165118A1 (en) 2024-05-23
ES2912929T3 (es) 2022-05-30
WO2018060501A3 (en) 2018-05-11
EP3518933A2 (en) 2019-08-07
EP3518933B1 (en) 2022-03-16
CN110312512B (zh) 2023-05-09
IL300580A (en) 2023-04-01
IL265700B1 (en) 2023-03-01
HRP20220708T1 (hr) 2022-07-22
RS63300B1 (sr) 2022-07-29
AU2017336363B2 (en) 2022-08-04
US20210401841A1 (en) 2021-12-30
HUE059101T2 (hu) 2022-10-28
US20220370462A1 (en) 2022-11-24
EP4094766A1 (en) 2022-11-30
AU2022241582A1 (en) 2022-10-27
NZ752916A (en) 2022-09-30
US11033551B2 (en) 2021-06-15

Similar Documents

Publication Publication Date Title
IL265700A (en) Methods for treating uterine fibroids and endometrial disease
IL253162A0 (en) Devices and methods for the treatment of cancers and discoveries
SG11201803619VA (en) Three-dimensional memory apparatuses and methods of use
GB201413473D0 (en) Security device and method of manufacture thereof
GB2539390B (en) Security devices and methods of manufacture thereof
GB2544180B (en) Cover means and method of use thereof
HUE048931T2 (hu) Eljárások és berendezések mérési korlátozások kialakítására
GB2550168B (en) Security device and method of manufacture
IL252726A0 (en) Uterine clamps to treat postpartum bleeding and to help restore the uterus
IL265359A (en) Modified Oligonucleotides and Methods of Use
IL272570A (en) Methods and preparations for the detection and treatment of endometriosis
SG10201405193QA (en) Hair extension device and related methods of manufacture
IL259096A (en) Peptides and methods of treating endometriosis using the same
GB202003768D0 (en) Electronic initiator sleeves and methods of use
GB201620675D0 (en) Photociode device and method of manufacture
GB201600263D0 (en) Fixation device and method of manufacture and use
GB2566975B (en) Security Device And Method Of Manufacture Thereof
PT3220908T (pt) Composições e métodos para o tratamento da endometriose
HK1250360A1 (zh) 袋和製作袋的方法
GB2526531B (en) Security device components and methods of manufacture thereof
AU2022241582B2 (en) Methods of treating uterine fibroids and endometriosis
IL246637A0 (en) Preparations and methods for the treatment of intracerebral hemorrhage
IL274190A (en) Methods for treating ischemic disease
PL3544822T3 (pl) Komponenty urządzenia zabezpieczającego i sposoby ich wytwarzania
IL248381A0 (en) A combination of brexpiprazole and nalemapine and its use in the treatment of drug-related disorders